Evidence map›Paper›PMID 40035501›Full record

Trial reportAnatolian journal of cardiology2025

Pharmaco-Invasive Strategy with Half-Dose Recombinant Human Prourokinase Versus Primary Percutaneous Coronary Intervention.

Chao Jiang, Jie Dou, Huihui Yang, Ruoling Guo, Jie Gao, Bo Liu, Hongjun Shu, Yanchun Hou, Lili Zhao, Jingtao Guo and 1 more

Abstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chao JiangSchool of Medicine, Chengde Medical University, Chengde, Hebei, China.
Jie DouSchool of Medicine, Chengde Medical University, Chengde, Hebei, China.
Huihui YangSchool of Medicine, Chengde Medical University, Chengde, Hebei, China.
Ruoling GuoSchool of Medicine, Chengde Medical University, Chengde, Hebei, China.
Jie GaoSchool of Medicine, Chengde Medical University, Chengde, Hebei, China.
Bo LiuDepartment of Cardiology, Chengde Central Hospital, Second Clinical College of Chengde Medical University, Chengde, Hebei, China.
Hongjun ShuDepartment of Cardiology, Chengde Central Hospital, Second Clinical College of Chengde Medical University, Chengde, Hebei, China.
Yanchun HouDepartment of Cardiology, Chengde Central Hospital, Second Clinical College of Chengde Medical University, Chengde, Hebei, China.
Lili ZhaoDepartment of Cardiology, Chengde Central Hospital, Second Clinical College of Chengde Medical University, Chengde, Hebei, China.
Jingtao GuoDepartment of Cardiology, Chengde Central Hospital, Second Clinical College of Chengde Medical University, Chengde, Hebei, China.
Donglei LuoDepartment of Cardiology, Chengde Central Hospital, Second Clinical College of Chengde Medical University, Chengde, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary percutaneous coronary intervention (PPCI) is preferred as the reperfusion option for patients with ST-segment elevation myocardial infarction (STEMI).

methodsThis study conducted the pharmacoinvasive strategy with half-dose recombinant human prourokinase (PHDP) trial to evaluate whether the PHPD encompassing early fibrinolysis coupled with timely catheterization, provides efficacy and safety similar to that of PPCI in STEMI patients. We randomly assigned patients with STEMI aged 18-80 years who presented within 24 h of their symptoms to receive either PHDP or PPCI.

resultsThere was no significant difference in the 2 arms for the primary endpoints, which were defined as thrombolysis in myocardial infarction (TIMI) flow grade 3, TIMI myocardial perfusion grade 3, and ST-segment resolution ≥70% 1 hour after percutaneous coronary intervention. The secondary endpoints, including slow flow/no-reflow (P < .001), malignant arrhythmia (P < .001), and hypotension (P < .001), occurred more frequently in the PPCI arm than in the PHDP arm. The combined 30-day follow-up outcomes occurred more often in the PPCI group than in the PHDP group (P = .032). There were no reported cases of in-hospital intracranial hemorrhage or major bleeding events; the rates of minor bleeding events were similar (P = .157).

conclusionAmong patients with STEMI presenting ≤24 hours after symptom onset who received the PHDP, the efficacy of complete epicardial and myocardial reperfusion was similar to that among patients who received the PPCI. In addition, PHDP was associated with a decreased risk of procedure-related complications. Conducting clinical efficacy and safety trials with the pharmacoinvasive strategy and the half-dose of fibrinolytic drug is warranted.

Indexed as

Fibrinolytic AgentsPercutaneous Coronary InterventionST Elevation Myocardial InfarctionUrokinase-Type Plasminogen ActivatorAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRecombinant ProteinsTreatment OutcomeYoung AdultFibrinolytic AgentsRecombinant ProteinsUrokinase-Type Plasminogen Activator

Identifiers

PMID40035501
PMCPMC11965947

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.